Overview

Lidocaine for Oxaliplatin-induced Neuropathy

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Oxaliplatin-induced neuropathy is a major dose-limiting side effect in patients with colorectal cancer treated with the FOLFOX chemotherapy regimen. Hypersensitivity to cold is the sensory hallmark of oxaliplatin-induced neuropathy, and it can predict the development of long-term neuropathy. In this study, the investigators aim to determine whether intravenous lidocaine can prevent oxaliplatin-induced cold hypersensitivity.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Lidocaine
Oxaliplatin